2024
Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis
Lansky A, Grubman D, Dwyer M, Zivadinov R, Parise H, Moses J, Shah T, Pietras C, Tirziu D, Gambone L, Leon M, Nazif T, Messé S. Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis. Journal Of The American College Of Cardiology 2024, 84: 712-722. PMID: 39142725, DOI: 10.1016/j.jacc.2024.05.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisClinical RelevanceDiffusion Magnetic Resonance ImagingFemaleHumansIschemic StrokeMalePostoperative ComplicationsProspective StudiesTranscatheter Aortic Valve ReplacementConceptsTranscatheter aortic valve replacementClinical ischemic strokeAcute brain infarctionDW-MRIReceiver operating characteristicIschemic strokeTranscatheter aortic valve replacement resultBrain infarctionPatient-level pooled analysisC-statisticBrain MRI lesionsAcute ischemic brain injuryDiffusion-weighted magnetic resonance imagingAortic valve replacementIndividual lesion volumesCore laboratory analysisIschemic brain injuryPredicting ischemic strokeMagnetic resonance imagingStroke Prevention TrialMRI lesionsValve replacementDW-MRI acquisitionsPatient-level dataPooled analysisMoving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR
Ahmad Y, Lansky A. Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR. JACC Cardiovascular Interventions 2024, 17: 1691-1692. PMID: 39048256, DOI: 10.1016/j.jcin.2024.06.017.Peer-Reviewed Original Research
2023
Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisAtrial FibrillationEmbolic Protection DevicesEmbolismHumansIntracranial EmbolismProspective StudiesRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd pointEffect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement
Shah T, Maarek R, See C, Huang H, Wang Y, Parise H, Forrest J, Lansky A. Effect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine 2023, 59: 3-8. PMID: 37573173, DOI: 10.1016/j.carrev.2023.07.022.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisAtrial FibrillationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRetrospective StudiesRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsAtrial fibrillationConduction disturbancesPrimary endpointStatin usersPacemaker placementRate of AFTranscatheter aortic valve replacementNew atrial fibrillationNew conduction disturbancesPersistent conduction disturbancesAortic valve replacementLong-term prognosisSmall retrospective studiesSignificant differencesPrior pacemakerIndex hospitalizationIntensity statinsValve replacementConsecutive patientsPropensity matchingProcedural complicationsStatin regimenRetrospective studyStatin usageCardiac proceduresImpact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisHumansRetrospective StudiesRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECGPublic Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗
Lansky A, Ahmad Y. Public Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗. JACC Cardiovascular Interventions 2023, 16: 177-178. PMID: 36697153, DOI: 10.1016/j.jcin.2022.11.010.Peer-Reviewed Original ResearchAortic ValveAortic Valve StenosisHumansRisk FactorsStrokeTranscatheter Aortic Valve ReplacementTreatment Outcome
2022
Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial.
Jagielak D, Targonski R, Frerker C, Abdel-Wahab M, Wilde J, Werner N, Lauterbach M, Leick J, Grygier M, Misterski M, Erglis A, Narbute I, Witkowski AR, Adam M, Frank D, Gatto F, Schmidt T, Lansky AJ. Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial. EuroIntervention 2022, 18: 590-597. PMID: 35608032, PMCID: PMC10241272, DOI: 10.4244/eij-d-22-00238.Peer-Reviewed Original ResearchMeSH KeywordsDiffusion Magnetic Resonance ImagingEmbolic Protection DevicesHumansIntracranial EmbolismStrokeTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve implantationAortic valve implantationLesion volumeValve implantationTechnical successC trialSingle lesionCerebral embolic protection devicesPerformance endpointBrain diffusion-weighted magnetic resonance imagingLarge single lesionsPrimary safety endpointBrain lesion volumeDiffusion-weighted magnetic resonance imagingCerebral protection systemSingle-arm studyEmbolic protection devicesPrimary performance endpointRate of deathMagnetic resonance imagingTAVI casesTAVI patientsVARC-2Cerebrovascular eventsPrimary endpoint
2021
Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis
Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, Kennon S, Forrest JK, Mathur A, Mullen MJ, Lansky A, Baumbach A. Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. JACC Cardiovascular Interventions 2021, 14: 2083-2096. PMID: 34620388, DOI: 10.1016/j.jcin.2021.07.058.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisCoronary Artery DiseaseHeart Valve ProsthesisHumansRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsAortic valve replacementCoronary artery diseaseAortic stenosisHemodynamic statusCoronary revascularizationValve replacementAssessment of CADPatients Undergoing Aortic Valve ReplacementConcomitant coronary artery diseaseImpact of ASSignificant coronary artery diseaseConcomitant aortic stenosisRole of revascularizationSevere aortic stenosisThird of patientsCohort of patientsDual pathologyArtery diseaseTherapeutic challengeCertain patientsMyocardial ischemiaCoronary assessmentPatientsRevascularizationMultidisciplinary teamA randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisEmbolic Protection DevicesHumansProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesionsRandomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II
Nazif TM, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, Horwitz P, Makkar R, Stoler R, Forrest J, Messé S, Dickerman S, Brennan J, Zivadinov R, Dwyer MG, Lansky AJ, Investigators R. Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II. JACC Cardiovascular Interventions 2021, 14: 515-527. PMID: 33663779, DOI: 10.1016/j.jcin.2020.11.011.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisEmbolic Protection DevicesHumansProspective StudiesRisk FactorsSingle-Blind MethodStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementAortic valve replacementSafety endpointValve replacementProcedure-related ischemic strokeCerebral embolic protectionComposite efficacy endpointPrimary safety endpointCerebral embolizationCerebral protectionEfficacy endpointII trialCerebral injuryIschemic strokeEmbolic protectionPatientsDrug AdministrationUS sitesU.S. FoodEndpointData reviewTrialsMulticenterEmbolizationInjury
2020
Cerebral Embolic Protection Burden of Proof ∗
Lansky A, Pietras C, Shah T. Cerebral Embolic Protection Burden of Proof ∗. JACC Cardiovascular Interventions 2020, 13: 2156-2158. PMID: 32972579, DOI: 10.1016/j.jcin.2020.06.030.Peer-Reviewed Original ResearchAortic Valve StenosisBrain IschemiaHumansIntracranial EmbolismIschemic StrokeStrokeTranscatheter Aortic Valve ReplacementTreatment OutcomeCerebral Embolic Protection Finding a Black Cat in a Coal Cellar ∗
Lansky A, Saito Y, Kaple R. Cerebral Embolic Protection Finding a Black Cat in a Coal Cellar ∗. JACC Cardiovascular Interventions 2020, 13: 869-871. PMID: 32273099, DOI: 10.1016/j.jcin.2019.12.013.Peer-Reviewed Original ResearchAortic Valve StenosisCoalHumansIntracranial EmbolismTranscatheter Aortic Valve ReplacementTreatment OutcomeAdjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology 2020, 5: 92-101. PMID: 31721980, DOI: 10.1001/jamacardio.2019.4367.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementAdjunctive antithrombotic therapyDual antiplatelet therapyAntithrombotic therapyAntiplatelet therapyValve replacementAortic stenosisAortic stenosis (AS) undergoing transcatheter aortic valve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementGuideline-recommended regimenOral anticoagulant useSevere aortic stenosisSingle antiplatelet therapySymptomatic aortic stenosisPatient risk factorsOngoing clinical trialsRisk prediction modelMajor bleedingOral anticoagulationAnticoagulant useStroke riskTAVR proceduresThrombotic risk
2019
Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation
Krittanawong C, Kumar A, Wang Z, Johnson KW, Rastogi U, Narasimhan B, Kaplin S, Virk HUH, Baber U, Tang W, Lansky AJ, Stone GW. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2019, 125: 251-257. PMID: 31759517, DOI: 10.1016/j.amjcard.2019.10.014.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationBaseline heart failureAortic valve implantationHeart failureAdditional independent predictorsHospital mortalityEjection fractionIndependent predictorsValve implantationPresence of HFReduced ejection fractionSevere aortic stenosisIn-Hospital MortalityPredictors of mortalityPotential baseline confoundersAortic valve stenosisICD-9 codesAbsence of depressionTAVI patientsHF patientsAortic stenosisValve stenosisLiver diseaseMultivariable analysisPatient selection
2018
TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy.
Lansky A, Ghare MI, Tchétché D, Baumbach A. TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. EuroIntervention 2018, 14: ab53-ab63. PMID: 30158096, DOI: 10.4244/eij-d-18-00454.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisBrainHeart Valve Prosthesis ImplantationHumansNeuroprotectionRisk FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve implantationAortic stenosisAdjunctive pharmacotherapySevere symptomatic aortic stenosisIntermediate-risk patientsSymptomatic aortic stenosisHigh-risk patientsAortic valve implantationSurgical valve replacementEvidence of neuroprotectionNeurologic eventsDevastating complicationNeurologic injuryValve implantationValve replacementCurrent evidenceNeuroprotectionPharmacotherapyPatientsPreferred methodComplicationsStenosisInjuryStrokeIncidenceCarotid Disease and Stroke After Transcatheter Aortic Valve Replacement
Lansky AJ, Ghare MI, Pietras C. Carotid Disease and Stroke After Transcatheter Aortic Valve Replacement. Circulation Cardiovascular Interventions 2018, 11: e006826. PMID: 29895605, DOI: 10.1161/circinterventions.118.006826.Peer-Reviewed Original Research
2017
The SURTAVI study: TAVI for patients with intermediate risk.
Jones DA, Tchétché D, Forrest J, Hellig F, Lansky A, Moat N. The SURTAVI study: TAVI for patients with intermediate risk. EuroIntervention 2017, 13: e617-e620. PMID: 28781252, DOI: 10.4244/eijv13i5a97.Peer-Reviewed Original ResearchAortic ValveAortic Valve StenosisHeart Valve Prosthesis ImplantationHumansRisk FactorsTranscatheter Aortic Valve ReplacementTreatment Outcome
2016
Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial)
Lansky AJ, Brown D, Pena C, Pietras CG, Parise H, Ng VG, Meller S, Abrams KJ, Cleman M, Margolis P, Petrossian G, Brickman AM, Voros S, Moses J, Forrest JK. Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial). The American Journal Of Cardiology 2016, 118: 1519-1526. PMID: 27645761, DOI: 10.1016/j.amjcard.2016.08.013.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAortic ValveAortic Valve StenosisBrainBrain IschemiaDiffusion Magnetic Resonance ImagingFemaleFollow-Up StudiesHumansIncidenceIntracranial EmbolismMalePostoperative ComplicationsPrognosisProspective StudiesRisk AssessmentRisk FactorsSurvival RateTranscatheter Aortic Valve ReplacementUnited StatesConceptsTranscatheter aortic valve implantationAortic valve implantationNeurologic injuryValve implantationNeurologic impairmentMagnetic resonance imaging lesionsCognitive AssessmentMontreal Cognitive Assessment scoreCerebral ischemic lesionsNew neurologic impairmentSubclinical cerebral infarctsDiffusion-weighted magnetic resonance imagingTotal lesion volumeCognitive Assessment scoreMontreal Cognitive AssessmentMagnetic resonance imagingCerebral embolizationCerebral infarctsNeurologic complicationsCerebral infarctionImaging lesionsMost patientsOvert strokeConsecutive patientsIschemic lesionsTranscatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials)
Forrest JK, Adams DH, Popma JJ, Reardon MJ, Deeb GM, Yakubov SJ, Hermiller JB, Huang J, Skelding KA, Lansky A. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). The American Journal Of Cardiology 2016, 118: 396-402. PMID: 27346591, DOI: 10.1016/j.amjcard.2016.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisCause of DeathComorbidityFemaleFrail ElderlyHumansIncidenceMaleMortalityPostoperative ComplicationsPostoperative HemorrhageSeverity of Illness IndexSex FactorsStrokeTranscatheter Aortic Valve ReplacementTreatment OutcomeVentricular Dysfunction, LeftConceptsTranscatheter aortic valve replacementAortic valve replacementCoreValve prosthesisValve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementLeft ventricular systolic functionWomen Versus MenMajor vascular complicationsSymptomatic aortic stenosisIncidence of strokeProcedure-related complicationsVentricular systolic functionCoronary artery diseaseLife-threatening bleedsSignificant baseline differencesGender-related differencesCause mortalityVascular complicationsBaseline characteristicsPatient characteristicsPrevious strokeSystolic functionAortic stenosisArtery disease
2015
The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement
Baumbach A, Pietras C, Lansky A. The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement. Expert Review Of Medical Devices 2015, 12: 649-651. PMID: 26364995, DOI: 10.1586/17434440.2015.1086642.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHeart Valve Prosthesis ImplantationHumansIntracranial EmbolismStrokeTranscatheter Aortic Valve ReplacementConceptsTranscatheter aortic valve implantationAortic valve implantationValve implantationTranscatheter aortic valve replacementIschemic cerebral eventsAortic valve replacementPrevention of strokeCerebral embolizationEmbolic strokeCerebral eventsEmbolic eventsValve replacementEmbolic lesionsClinical studiesNeurocognitive impairmentNeurocognitive functionMemory lossVessel ostiumStrokeBrain circulationImplantationEmbolizationOstiumLesionsIncidence